Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof
AssigneesCentre National de la Recherche Scientifique (CNRS), Universite Pierre Et Marie Curie (Paris 6), Assitance Publique—Hopitaux De Paris, Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet), Universidad Catolica De Corcoba (Ucc)
InventorsDavid Klatzmann, Eliane Piaggio, Hugo Daniel Luján
Life of this patent
Estimating the term…
Abstract
The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as Giardia parasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.
Claims11
An immunogenic composition against an antigen comprising:
- an antigen bound to a polypeptide, wherein the polypeptide:
- is heterologous to the antigen, comprises 10 to 14 CXXC motifs, wherein C represents a cysteine residue and X any amino acid residue, is a variable surface protein (VSP), a VSP-like protein of a microorganism or a fragment thereof, and is able to attach to epithelial cells of the gut, and wherein CXXC corresponds to SEQ ID NO 1, wherein the microorganism is selected from the group consisting of Giardia, Tetrahymena, Paramecium and Entamoeba species, wherein the polypeptide is bound to a vector particle containing said antigen, and wherein the vector particle is a viral particle, a viral-like particle (VLP) or a nanoparticle.
A method of immunization of a subject against an influenza A H5N1, wherein said method comprises administering to said subject said antigen bound to a polypeptide, wherein the polypeptide:
- is heterologous to said antigen, comprises 10 to 14 CXXC motifs, wherein C represents a cysteine residue and X any amino acid residue, is a variable surface protein (VSP), a VSP-like protein of a microorganism or a fragment thereof, and is able to attach to epithelial cells of the gut, and wherein CXXC corresponds to SEQ ID NO 1, wherein the microorganism is selected from the group consisting of Giardia, Tetrahymena, Paramecium and Entamoeba species, wherein the polypeptide is bound to a vector particle containing said antigen, and wherein the vector particle is a viral particle, a viral-like particle (VLP) or a nanoparticle.
Dependencies are inferred from the claim text.